PL2688578T3 - Inhibitory mia (aktywności hamującej czerniaka) do zapobiegania i leczenia bielactwa nabytego - Google Patents

Inhibitory mia (aktywności hamującej czerniaka) do zapobiegania i leczenia bielactwa nabytego

Info

Publication number
PL2688578T3
PL2688578T3 PL12710120T PL12710120T PL2688578T3 PL 2688578 T3 PL2688578 T3 PL 2688578T3 PL 12710120 T PL12710120 T PL 12710120T PL 12710120 T PL12710120 T PL 12710120T PL 2688578 T3 PL2688578 T3 PL 2688578T3
Authority
PL
Poland
Prior art keywords
mia
inhibitors
preventing
inhibitory activity
melanoma inhibitory
Prior art date
Application number
PL12710120T
Other languages
English (en)
Inventor
Matteo BORDIGNON
Original Assignee
Matteo BORDIGNON
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matteo BORDIGNON filed Critical Matteo BORDIGNON
Publication of PL2688578T3 publication Critical patent/PL2688578T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/207—Pigmentation disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL12710120T 2011-03-22 2012-03-12 Inhibitory mia (aktywności hamującej czerniaka) do zapobiegania i leczenia bielactwa nabytego PL2688578T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000134A ITRM20110134A1 (it) 2011-03-22 2011-03-22 Inibitori di mia (attività inibitoria melanoma) per identificare, prevenire e curare la vitiligine
EP12710120.2A EP2688578B1 (en) 2011-03-22 2012-03-12 Mia (melanoma inhibitory activity) inhibitors for preventing and curing vitiligo
PCT/IB2012/051141 WO2012127352A2 (en) 2011-03-22 2012-03-12 Mia (melanoma inhibitory activity) inhibitors for detecting, preventing and curing vitiligo

Publications (1)

Publication Number Publication Date
PL2688578T3 true PL2688578T3 (pl) 2019-07-31

Family

ID=43977364

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12710120T PL2688578T3 (pl) 2011-03-22 2012-03-12 Inhibitory mia (aktywności hamującej czerniaka) do zapobiegania i leczenia bielactwa nabytego

Country Status (15)

Country Link
US (1) US20140004130A1 (pl)
EP (1) EP2688578B1 (pl)
JP (1) JP2014514285A (pl)
KR (1) KR20140041466A (pl)
CN (1) CN103930122A (pl)
AU (1) AU2012232753A1 (pl)
BR (1) BR112013024301A2 (pl)
DK (1) DK2688578T3 (pl)
ES (1) ES2730704T3 (pl)
IT (1) ITRM20110134A1 (pl)
MX (1) MX2013010891A (pl)
PL (1) PL2688578T3 (pl)
PT (1) PT2688578T (pl)
RU (1) RU2013147195A (pl)
WO (1) WO2012127352A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190352335A1 (en) * 2016-12-19 2019-11-21 Hanmi Pharm. Co., Ltd. Brain targeting long-acting protein conjugate
EP3936138A1 (en) * 2020-07-09 2022-01-12 Bella Aurora Labs, S.A. Pharmaceutical composition for the treatment of vitiligo
EP4292581A1 (en) 2022-06-16 2023-12-20 Bella Aurora Labs, S.A. Hair repigmenting composition
EP4385515A1 (en) 2022-12-16 2024-06-19 Bella Aurora Labs, S.A. Composition for skin repigmentation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA945278B (en) * 1993-07-20 1996-01-19 Boehringer Mannheim Gmbh Melanoma-inhibiting protein
DE19653358A1 (de) * 1996-12-20 1998-06-25 Boehringer Mannheim Gmbh Immunoassay zum Nachweis von MIA
NZ520346A (en) * 2000-03-23 2004-07-30 Akzo Nobel Nv Use of MIA in immunotherapy
JP2005528338A (ja) * 2002-01-29 2005-09-22 アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 「黒色腫阻害活性物質」（ｍｉａ）を阻害する方法
ES2289544T3 (es) * 2003-08-12 2008-02-01 Antisense Pharma Gmbh Oligonucleotido antisentido para inhibir la actividad inhibidora de melanoma mia.
WO2013033395A1 (en) * 2011-08-30 2013-03-07 Loyola University Chicago MUTANT HSP70i TO PREVENT AUTOIMMUNE DISEASE

Also Published As

Publication number Publication date
RU2013147195A (ru) 2015-04-27
CN103930122A (zh) 2014-07-16
PT2688578T (pt) 2019-05-08
ES2730704T3 (es) 2019-11-12
KR20140041466A (ko) 2014-04-04
WO2012127352A2 (en) 2012-09-27
WO2012127352A8 (en) 2014-03-13
JP2014514285A (ja) 2014-06-19
US20140004130A1 (en) 2014-01-02
WO2012127352A3 (en) 2012-12-27
MX2013010891A (es) 2014-03-12
ITRM20110134A1 (it) 2012-09-23
EP2688578B1 (en) 2019-03-27
DK2688578T3 (da) 2019-06-11
AU2012232753A1 (en) 2014-01-23
BR112013024301A2 (pt) 2018-04-17
EP2688578A2 (en) 2014-01-29

Similar Documents

Publication Publication Date Title
HRP20180953T1 (hr) Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe
IL245309A0 (en) Heterocyclic tricyclic compounds and jak inhibitors
EP2890678A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2903613A4 (en) INHIBITORS OF IRAQ4 ACTIVITY
EP2903617A4 (en) INHIBITORS OF IRAQ4 ACTIVITY
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
HK1198827A1 (en) Dyrk1 inhibitors and uses thereof dyrk1
GB201103526D0 (en) Selective glycosidase inhibitors and uses thereof
EP2890679A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2723753A4 (en) SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2935283A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2914604A4 (en) GLYCOSIDASE INHIBITORS AND ASSOCIATED APPLICATIONS
EP2726468A4 (en) SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2890675A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2890676A4 (en) GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2744338A4 (en) SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
EP2726492A4 (en) SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2691407A4 (en) GLYCOSIDASE SELECTIVE INHIBITORS AND USES THEREOF
EP2688899A4 (en) GLYCOSIDASE SELECTIVE INHIBITORS AND USES THEREOF
EP2691888A4 (en) SEGMENTS OF DEFINITION AND MATCHING
EP2521451A4 (en) INHIBITORS OF THE HEDGEHOG PATH
HRP20180543T1 (hr) Spojevi uree i njihova upotreba kao inhibitora enzima
EP2802324A4 (en) BENZHYDROL-PYRAZOLE DERIVATIVES HAVING KINASE INHIBITING ACTIVITY AND USES THEREOF
EP2688901A4 (en) INHIBITORS OF 17SS-HSD1, 17SS-HSD3 AND 17SS-HSD10
EP2658972A4 (en) MELANOMA TREATMENT